drugset
drugset / Trial / NCT06197178

A Study of LCAR-G08 in Subjects With Advanced Gastrointestinal Tumors Expressing Guanylyl Cyclase C (GCC)

NCT06197178 ↗

Phase 1 Terminated 17 enrolled Peking University Nanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 1, single-arm, open-label, dose escalation and expansion study of LCAR-G08 in adult subjects with advanced gastrointestinal tumors expressing guanylyl cyclase C (GCC).

Timeline

Start
2023-12-28
Primary completion
2025-10-22
Completion
2025-10-22

Outcome

Outcome not reported

Stopped: “achieved the proof of concept”

Drugs

EvaluationDrugModalityDoseRoute
Subject LCAR-G08 Unknown — —
Background Cyclophosphamide Other / unclassified — —
Background Fludarabine Small molecule — —

Indications

No indication recorded.